“He (Han) is an academic who sits on the border with industry, so he understands that translational perspective,” Peralta told TechCrunch in an interview. “We came together with the opportunity to use Namshik’s work, but within the cardiovascular space.”
CardiaTec is tackling the crux of the problem: The average expense of progressing a drug candidate from discovery through launch is around $2.2 billion, and that cost is driven substantively by the fact that 90% of potential candidates fail in the process, according to Deloitte. CardiaTec is setting out to “decode” the biology of CVDs.